Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Profiling of differential RNAs in LY500307-treated B16 cells and control-treated B16 cells

ABSTRACT: In this study, we examined the differential RNA profile of LY500307-treated B16 cells compared with control-treated B16 cells

ORGANISM(S): Mus musculus

PROVIDER: GSE110769 | GEO | 2018/04/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Profiling of differential RNAs in LY500307-treated B16 cells and control-treated B16 cells

Project description:Profiling of differential RNAs in LY500307-treated B16 cells and control-treated B16 cells

| PRJNA434513 | ENA

Profiling of differential RNAs in LY500307-treated 4T1 cells and control cells

Project description:In this study, we examined the differential RNA profile of LY500307-treated 4T1 cells compared with control-treated 4T1 cells

2018-04-25 | GSE110770 | GEO

Profiling of differential RNAs in LY500307-treated 4T1 cells and control cells

Project description:Profiling of differential RNAs in LY500307-treated 4T1 cells and control cells

| PRJNA434514 | ENA

Expression profile from doxorubicine treated B16 melanoma cells

Project description:Tumor resistance to anti-cancer drugs is a major huddle in chemotherapy. To identify cancer genes that contribute to chemoresistance, B16 mouse melanoma cells were used as a model. We used microarrays to decipher the specific gene regulation in doxorubicine treated B16 mouse melanoma cells. Keywords: Time course

2008-07-18 | GSE12142 | GEO

Differential expression profiles of RNAs in mouse melanoma cells treated with ATRA and PB-4

Project description:We extracted the total RNA of B16 cells treated with ATRA or PB-4 for 48 h and used RNA-seq technology to detect differentially expressed RNAs such as lncRNAs, miRNAs, and mRNAs in B16 cells. The results showed that compared with the normal control group, 102 lncRNAs, 24 miRNAs, and 761 mRNAs showed differential expression in the ATRA-treated group, and 306 lncRNAs, 105 miRNAs, and 2567 mRNAs showed differential expression in the PB-4-treated group.

2021-07-24 | GSE180667 | GEO

RNA-seq of B16-F10 cells cultured on the ECM of SMCs treated with siRNA and B16-F10 tumor conditioned media

Project description:The objective of this study was to profile B16-F10 cells grown in vitro on the extracelllular matrix generated by SMCs treated with siRNA and conditioned media

2017-09-19 | GSE96972 | GEO

Effect of caspase-3 and -7 knockout on doxorubicin treated B16 melanoma cells

Project description:To measure the immunosuppressive effect of caspase-3 and -7 in apoptosis, we generated B16 sgCTRL and sgCasp3/7 cells and treated them with doxorubicin

2022-08-05 | GSE210377 | GEO

Profiling of differential RNAs in alpha amanitin treated SORBS2-depleted ovarian cancer cells and control-treated SORBS2-depleted

Project description:In this study, we examined the differential RNA profile of alpha amanitin-treated SORBS2-depleted ovarian cancer cells compared with control-treated SORBS2-depleted cells

2018-02-20 | GSE101595 | GEO

RNA sequencing analysis of B16-F1, B16-F1R2 and B16-F1R2L

Project description:We wanted to correlate the protein cargo of secreted exosomes with gene expression pattern in B16-F1 and B16-F1R2. For that purpose, we performed RNA sequencing analysis of B16-F1, B16-F1R2 and B16-F1R2L (Fig.1E). We identified >3000 genes significantly up-regulated and >1000 significantly down-regulated in B16-F1R2 model compared to B16-F1, using a false discovery rate (FDR) of 0.05.

2021-07-28 | GSE150221 | GEO

Single cell transcriptomics of the tumor immune microenvironment from checkpoint blockade-treated B16 tumors edited with control or TBK1-targeting sgRNAs.

Project description:To examine the effect of tumor-specific TBK1 loss on the tumor immune microenvironment, we performed scRNA-seq on CD45+ cells from B16 tumors from mice treated with anti-PD-1 compared to mice treated with isotype control (IgG).

2022-11-07 | GSE217274 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data